Pidilizumab in the treatment of diffuse large B-cell lymphoma (Q38233257)

31 August 2017

Pidilizumab in the treatment of diffuse large B-cell lymphoma (English)

1 reference

31 August 2017

Locke J Bryan

1

1 reference

PubMed ID

25056108

31 August 2017

Leo I Gordon

series ordinal

2

1 reference

PubMed ID

25056108

31 August 2017

language of work or name

English

0 references

publication date

24 July 2014

1 reference

Expert Opinion on Biological Therapy

31 August 2017

1 reference

31 August 2017

14

1 reference

31 August 2017

9

1 reference

31 August 2017

1361-1368

1 reference

PD-1 and its ligands in tolerance and immunity

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Diagnostic and prognostic utility of PD-1 in B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.942637

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1517/14712598.2014.942637

1 reference

31 August 2017

1 reference

PubMed ID

25056108